

Monday 25 August		Tuesday 26 August	
	ARRIVAL	07:00-08:45	Breakfast
		09:00 - 09:45	Introductory Lecture I Where we are: Clinical Applications Wolfgang Weber, Munich
		09:45 - 09:50	
		09:50 - 10:35	Introductory Lecture II Where we are: Overview of (Radio-) Tracer Development Margret Schottelius, Lausanne
		10:35-10:40	
		10:40-10:55	coffee break
		10:55-11:40	Introductory Lecture III Where we go: Expansion of the Field Twan Lammers, Aachen
		11:40-11:45	
		11:45-13:00	Group Work 1
		13:00 - 14:00	Lunch
		14:00 - 15:00	Break
		15:00-15:15	Targeting ALDH1A1 for the identification and treatment of therapy resistant cancers Tim Witney, London
		15:15-15:20	
		15:20-15:35	Development of an anti-MET Shark Antibody to Target Non-Small Cell Lung Cancer Jayden West, Madison
		15:35-15:40	
		15:40-15:55	Radiolabeled PARP Inhibitor-Loaded Polymeric Micelles for Combination Radio-Chemotheranostics - Laura Schäfer, Aachen
		15:55-16:00	
16:00 - 17:15	Registration & Welcome Coffee	16:00-16:45	AI Tailored Theranostics Lalith Kumar, Munich/Vienna
		16:45-17:15	coffee break
17:15 - 17:45	Welcome & Introduction by the Committee (incl. introduction group work)	17:15-17:30	Radiolabelled Cholecystokinin-2 Receptor Antagonists Demonstrate Superior Tumour Targeting: Preclinical Studies with Theranostic Implications - Lennart Bohrmann, Basel
		17:30-17:35	
		17:35-17:50	Next-generation β -galactosidase targeting senescence radiotracers Francisco Reche-Pérez, Tübingen
		17:50-17:55	
17:45 - 18:30	Welcome Lecture Where it started: History of (Radio)Theranostics (Rodney Hicks, Melbourne)	17:55-18:10	Decoding Endocrine Resistance: Linking [18F]-FES PET Imaging and Ligand Affinity in Estrogen Receptor-Mutated Breast Cancer - Chloé Jean, Reims
		18:10-18:15	
		18:15-18:30	First Theranostic targeting of the prostatic acid phosphatase (ACP3) with [68Ga]Ga-OncoACP3-DOTA and [177Lu]Lu-OncoACP3-DOTA in prostate cancer patients - Philipp Backhaus, Münster
18:30-18:45		18:30-18:45	
18:45-19:45	Welcome Reception	18:45-19:00	Wine Tasting
19:45-20:00		19:45-20:00	
20:00	Dinner	20:00	Dinner

Wednesday 27 August		Thursday 28 August	
07:00-08:45	Breakfast	07:00-08:45	Breakfast
09:00 - 12:45	Excursion Guided Tour to Tuscan Town (Ticket required)	09:00 - 09:45	Detecting-Acting Systems Inge Hermann, Zurich
		09:45 - 09:50	
		09:50-10:05	Optimisation of PASylated ferritin nanocages for tumour-specific imaging in fluorescence-guided surgery - Valeria Giacobbo, Milan
		10:05-10:10	
		10:10-10:25	First Clinical Experience with the hybrid tracer [99mTc]Tc-PSMA-HSG: A Dual-Labeled Radiopharmaceutical for Hybrid Fluorescence & Radioguided Surgery in Prostate Cancer - Johanna Enke, Augsburg
		10:25-10:30	
		10:30-10:45	Towards theranostics-inspired interventions in neuropsychiatry with PET-MR-guided transcranial focused ultrasound - Ryan Ash, Stanford
		10:45-10:50	
		10:50-11:20	coffee break
		11:20-12:05	Trigger Responsive Systems Melita Irving, Lausanne
12:45 - 13:00		12:05-12:10	
		12:10-13:00	Group Work 3
13:00 - 14:00	Lunch	13:00 - 14:00	Lunch
14:00-14:45	Cell Delivery Systems I Paula Foster, London (CA)	14:00-14:45	Break
14:45-14:50			
14:50-15:35	Cell Delivery Systems II Jolanda de Vries, Nijmegen	14:45-15:30	Theranostic Implants Jeff Bulte, Baltimore
15:35-15:45	Poster Session Prep	15:30-15:35	
15:45-17:15	POSTER SESSION & COFFEE BREAK	15:35-15:50	Monitoring Biohybrid Tissue-Engineered Heart Valves with Multi-Color MPI and Complementary MRI and US - Elena Rama, Aachen
		15:50-15:55	
		15:55-16:10	Multicolour µCT enables to track therapeutic stem cells in a rat model of focal brain damage - Clement Capdeville, Lyon
		16:10-16:15	
		16:15-16:30	Theranostic Approach in Parkinson's Disease: Can Small Molecule Pairs Diagnose and Treat? - Ermal Ismalaj, San Sebastian
		16:30-16:35	
		16:35-17:00	coffee break
17:15-17:30	Heteronuclear MRI tracking of theranostic extracellular vesicles Andrea Galisova, Prague	17:00-17:45	Synthetic Biology Assaf Gilad, Michigan
17:30-17:35			
17:35-17:50	L-DOS47: A urease immunoconjugate capable of neutralizing the acidic tumor microenvironment in human cancer models - Dimitri Stowbur, Tübingen		
17:50-17:55		17:45-18:00	Excursion Prep
17:55-18:10	Oncolytic virus therapy as powerful promoter of a combined tumor antigen specific Th1 cell & immune checkpoint inhibitor (ICI)-based cancer immunotherapy - Marc Neumann, Tübingen	18:00-19:45	Excursion Monastery Olive Oil Mill or vineyard (tbc) short walk & guided tour
18:10-18:15			
18:15-19:00	Nanorobots Metin Siti, Istanbul		
19:00-19:45	Group Work 2		
20:00	Dinner	19:45-20:00	
		20:00	Dinner

	Friday 29 August
07:00-08:45	Breakfast
09:00 - 09:15	Best Poster Pitch
09:15-09:20	
09:20-10:00	Presentations Group Work
10:00h-10:15	coffee break
10:15 - 10:45	Summary / Highlight Lecture What we have learnt, (unresolved) challenges & what's next? <i>Bernd/Fabian/Tim?</i>
10:45-11:00	
11:00 - 11:15	Awarding & Farewell
11:15-11:45	ROOM CHECK-OUT
11:45-12:45	Early Lunch
	DEPARTURE